Clinical Trial Update: Vascular Endothelial Growth Factor (VEGF) Trap-Eye: Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration (AMD) [Phase 3]

View source ↗

Summary

Phase 3 results update on VEGF Trap-Eye (aflibercept) for wet age-related macular degeneration, with trial outcomes posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• VEGF Trap-Eye (aflibercept)

Snippet

Sponsor: Bayer | Conditions: Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2012-01-23